Table 1.
Relationship of Hsp27 expression with clinicopathological features,TopoIIα and therapeutic effect of anthracycline-based NAC in LABC patients.
| Terms | N (%) | Hsp27 expression (%) | Chi-square | P | |
|---|---|---|---|---|---|
| Negative (n=55) | Positive (n=48) | ||||
| Clinicopathological features | |||||
| Age | |||||
| ≤50 | 47 (45.6) | 25 (53.2) | 22 (46.8) | 0.001 | 0.969 |
| >50 | 56 (54.4) | 30 (53.6) | 26 (46.4) | ||
| Menopausal status | |||||
| Pre | 52 (50.5) | 26 (50.0) | 26 (50.0) | 0.487 | 0.485 |
| Post | 51 (49.5) | 29 (56.9) | 22 (43.1) | ||
| Nodal status | |||||
| N1 | 18 (17.5) | 14 (77.8) | 4 (22.2) | 5.210 | 0.022 |
| N2-N3 | 85 (82.5) | 41 (48.2) | 44 (51.8) | ||
| TNM stage | |||||
| TNM2-TNM3a | 34 (33.0) | 19 (55.9) | 15 (44.1) | 0.126 | 0.723 |
| TNM3b-TNM3c | 69 (67.0) | 36 (52.2) | 33 (47.8) | ||
| Histological grade | |||||
| well/moderately differentiated | 41 (39.8) | 34 (82.9) | 7 (17.1) | 23.867 | <0.001 |
| poorly differentiated | 62 (60.2) | 21 (33.9) | 41 (66.1) | ||
| Ki67 change (after chemotherapy) | |||||
| Reduced | 78 (75.7) | 47 (60.3) | 31 (39.7) | 6.074 | 0.014 |
| Elevated | 25 (24.3) | 8 (32.0) | 17 (68.0) | ||
| ER | |||||
| Negative | 38 (36.9) | 18 (47.4) | 20 (52.6) | 0.880 | 0.348 |
| Positive | 65 (63.1) | 37 (56.9) | 28 (43.1) | ||
| PR | |||||
| Negative | 47 (45.6) | 23 (48.9) | 24 (51.1) | 0.692 | 0.406 |
| Positive | 56 (54.4) | 32 (57.1) | 24 (42.9) | ||
| Her-2 | |||||
| Negative | 66 (64.1) | 34 (51.5) | 32 (48.5) | 0.262 | 0.609 |
| Positive | 37 (35.9) | 21 (56.8) | 16 (43.2) | ||
| Molecular subtype | |||||
| Luminal A | 8 (7.7) | 6 (75.0) | 2 (25.0) | – | 0.317* |
| Luminal B1 | 45 (43.7) | 22 (48.9) | 23 (51.1) | ||
| Luminal B2 | 14 (13.6) | 10 (71.4) | 4 (28.6) | ||
| TNBC** | 13 (12.6) | 5 (38.5) | 8 (61.5) | ||
| HER2-enriched | 23 (22.3) | 12 (52.2) | 11 (47.8) | ||
| TopoIIα | |||||
| Negative | 29 (28.2) | 4 (13.8) | 25 (86.2) | 25.443 | <0.001 |
| Positive | 74 (71.8) | 51 (68.9) | 23 (31.1) | ||
| Therapeutic effectiveness | |||||
| Chemotherapeutic efficacy | |||||
| CR+PR | 79 (76.7) | 47 (59.5) | 32 (40.5) | 5.062 | 0.024 |
| SD+PD | 24 (23.3) | 8 (33.3) | 16 (66.7) | ||
| Pathologic complete response | |||||
| yes | 11 (10.7) | 11 (100.0) | 0 (0.0) | 10.748 | 0.001 |
| no | 92 (89.3) | 44 (47.8) | 48 (52.2) | ||
Statistically significant values (P< 0.05) are given in italics.* Fisher’s Exact Test. ** Triple-Negative Breast Cancer.